Seelos Therapeutics (SEEL)

Apricus Biosciences' (APRI) CEO Rich Pascoe on Q4 2017 Results - Earnings Call Transcript
March 1, 2018 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Richard Pascoe on Q3 2017 Results - Earnings Call Transcript
Nov. 5, 2017 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences's (APRI) CEO Richard Pascoe on Q2 2017 Results - Earnings Call Transcript
Aug. 2, 2017 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Richard Pascoe on Q1 2017 Results - Earnings Call Transcript
May 11, 2017 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Richard Pascoe on Q4 2016 Results - Earnings Call Transcript
March 13, 2017 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Rich Pascoe on Q3 2016 Results - Earnings Call Transcript
Nov. 8, 2016 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Richard Pascoe on Q2 2016 Results - Earnings Call Transcript
Aug. 7, 2016 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Rich Pascoe on Q1 2016 Results - Earnings Call Transcript
May 9, 2016 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences (APRI) Q4 2015 Results - Earnings Call Webcast
March 9, 2016 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Rich Pascoe on Q4 2015 Results - Earnings Call Transcript
March 9, 2016 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Rich Pascoe on Q3 2015 Results - Earnings Call Transcript
Nov. 9, 2015 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences (APRI) Q3 2015 Results - Earnings Call Webcast
Nov. 5, 2015 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences (APRI) Q2 2015 Results - Earnings Call Webcast
Aug. 5, 2015 | Price: Free! | Source: Seeking Alpha

Apricus' (APRI) CEO Rich Pascoe on Q2 2015 Results - Earnings Call Transcript
Aug. 5, 2015 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences (APRI) Q1 2015 Results - Earnings Call Webcast
May 11, 2015 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Rich Pascoe on Q1 2015 Results - Earnings Call Transcript
May 11, 2015 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Rich Pascoe on Q4 2014 Results - Earnings Call Transcript
March 16, 2015 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences (APRI) Q4 2014 Results - Earnings Call Webcast
March 16, 2015 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Rich Pascoe on Q3 2014 Results -- Earnings Call Transcript
Nov. 10, 2014 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' (APRI) CEO Richard Pascoe on Q2 2014 Results - Earnings Call Transcript
Aug. 12, 2014 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences (APRI) CEO Rich Pascoe on Q1 2014 Results - Earnings Call Transcript
May 12, 2014 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' CEO Discusses Q4 2013 Results - Earnings Call Transcript
March 17, 2014 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences Management Discusses Q3 2013 Results - Earnings Call Transcript
Nov. 13, 2013 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences Management Discusses Q2 2013 Results - Earnings Call Transcript
Aug. 12, 2013 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences Inc - Business Update Call Transcript
Aug. 12, 2013 | Price: Free! | Source: Earnings Impact

Apricus Biosciences, Inc. - Special Call
June 10, 2013 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences Management Discusses Q1 2013 Results - Earnings Call Transcript
May 10, 2013 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences Management Discusses 2012 Results - Earnings Call Transcript
March 18, 2013 | Price: Free! | Source: Seeking Alpha

NexMed Q3 2012 Earnings Conference Call Transcript
Nov. 9, 2012 | Price: $106.00 | Source: Thomson

Apricus Biosciences Management Discusses Q3 2012 Results - Earnings Call Transcript
Nov. 9, 2012 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Aug. 11, 2012 | Price: Free! | Source: Seeking Alpha

Apricus Biosciences Inc Q2 2012 Earnings Conference Call Transcript
Aug. 10, 2012 | Price: $54.00 | Source: Thomson

Apricus Biosciences to Own Revenue Generating Leading French Drug Sales & Marketing Company Confere
June 20, 2012 | Price: $54.00 | Source: Thomson

Apricus Biosciences Inc at Jefferies Global Healthcare Conference Transcript
June 7, 2012 | Price: $54.00 | Source: Thomson

Apricus Biosciences Inc Q1 2012 Earnings Conference Call Transcript
May 10, 2012 | Price: $54.00 | Source: Thomson

Recent filings

Securities to be offered to employees in employee benefit plans - May 21, 2020

Material Modification to Rights of Security - May 21, 2020

Material Modification to Rights of Security - May 19, 2020

Seelos Therapeutics director just declared ownership of no shares of Seelos Therapeutics - May 15, 2020

Seelos Therapeutics director was just granted 40,000 options - May 15, 2020

Seelos Therapeutics Announces Appointment Of Judith Dunn To The Board Of Directors - May 15, 2020

Seelos Therapeutics Just Filed Its Quarterly Report: Net Loss Per Share B... - May 7, 2020

Seelos: Form, Schedule Or Registration State No Filing Party: Date Filed: **** IMPORTANT REMINDER **** Dear Seelos Therapeutics, Inc. Stockholder: - May 4, 2020

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - April 24, 2020

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - April 17, 2020

Seelos Therapeutics releases salary data. CEO received compensation of $677,750 - April 13, 2020

Other preliminary proxy statements - April 1, 2020

Departure of Directors or Certain - March 30, 2020

Seelos Therapeutics Just Filed Its Annual Report: 12. Subsequent Event... - March 17, 2020

Seelos Therapeutics Announces Closing Of Public Offering Of Common Stock - March 16, 2020

Seelos Therapeutics just filed a prospectus, suggesting it plans to soon issue some securities - March 12, 2020

Seelos Therapeutics Announces Pricing Of $4.5 Million Public Offering Of Common Stock - March 12, 2020

Seelos Therapeutics just filed a prospectus, suggesting it plans to soon issue some securities - March 11, 2020

Confidential treatment order - March 6, 2020

Altium Growth GP, LLC just issued a filing suggesting it has sold all of its Seelos Therapeutics - Feb. 14, 2020

Steven Boyd just issued a filing suggesting it has sold all of its Seelos Therapeutics - Feb. 14, 2020

Seelos Therapeutics Announces Closing Of Public Offering Of Common Stock - Feb. 13, 2020

Ligand Pharmaceuticals Incorporated just provided an update on share ownership of Seelos Therapeutics - Feb. 12, 2020

Seelos Therapeutics Announces Pricing Of $5 Million Public Offering Of Common Stock - Feb. 11, 2020

Seelos Therapeutics just filed a prospectus, suggesting it plans to soon issue some securities - Feb. 11, 2020

Seelos Therapeutics Just Received a Notice of Effectiveness - Feb. 10, 2020

Heights Capital Management, Inc. just provided an update on share ownership of Seelos Therapeutics - Feb. 10, 2020

General form for registration of securities under the Securities Act of 1933 - Feb. 7, 2020

General form for registration of securities under the Securities Act of 1933 - Feb. 5, 2020

General form for registration of securities under the Securities Act of 1933 - Jan. 30, 2020

Filing under Securities Act Rules 163/433 of free writing prospectuses - Jan. 30, 2020

General form for registration of securities under the Securities Act of 1933 - Jan. 22, 2020

Phoenixus AG just provided an update on share ownership of Seelos Therapeutics - Jan. 16, 2020

Seelos Therapeutics director was just granted 16,000 options - Jan. 7, 2020

Seelos Therapeutics director was just granted 16,000 options - Jan. 7, 2020

Seelos Therapeutics director was just granted 16,000 options - Jan. 7, 2020

Major owner of Seelos Therapeutics was just granted 731,000 options - Jan. 7, 2020

Seelos Therapeutics director was just granted 16,000 options - Jan. 7, 2020

Seelos Therapeutics just filed a prospectus, suggesting it plans to soon issue some securities - Jan. 3, 2020

Entry into a Material Definitive - Jan. 3, 2020

Seelos Therapeutics Just Received a Notice of Effectiveness - Dec. 2, 2019

Seelos Therapeutics just filed a prospectus, suggesting it plans to soon issue some securities - Dec. 2, 2019

General form for registration of securities under the Securities Act of 1933 - Nov. 21, 2019

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - Nov. 7, 2019

Seelos Therapeutics Just Filed Its Quarterly Report: Net Loss Per Share B... - Nov. 7, 2019

Entry into a Material Definitive - Oct. 21, 2019

Notice of Exempt Offering of Securities, item 06b - Aug. 30, 2019

Entry into a Material Definitive - Aug. 27, 2019

Seelos Therapeutics just filed a prospectus, suggesting it plans to soon issue some securities - Aug. 26, 2019

Seelos Therapeutics just filed a prospectus, suggesting it plans to soon issue some securities - Aug. 23, 2019

Securities to be offered to employees in employee benefit plans - Aug. 15, 2019

Departure of Directors or Certain - Aug. 14, 2019

Seelos Therapeutics Just Filed Its Quarterly Report: Net Loss Per Share B... - Aug. 1, 2019

Seelos Therapeutics Announces Investigational New Drug Application Submission For Sls-005 - July 17, 2019

Seelos Therapeutics Announces Acquisition Of An Exclusive Worldwide License Of Gene Therapy Program To Address Parkinson'S Disease From Duke University - June 27, 2019

Seelos Therapeutics just filed a prospectus, suggesting it plans to soon issue some securities - June 18, 2019

Entry into a Material Definitive - June 18, 2019

Seelos Therapeutics Reports Q1 2019 Pipeline Update - May 21, 2019

Seelos Therapeutics Just Filed Its Quarterly Report: Net Loss Per Share B... - May 21, 2019

Notification of inability to timely file Form 10-Q or 10-QSB - May 15, 2019

Departure of Directors or Certain - May 13, 2019

Ligand Pharmaceuticals Incorporated just provided an update on share ownership of Seelos Therapeutics - April 15, 2019

Seelos Therapeutics releases salary data. CEO sees compensation rise 21% - April 12, 2019

Changes in - April 8, 2019

Seelos Therapeutics Just Filed Its Annual Report: 12. SUBSEQUENT EVENT... - March 28, 2019

Departure of Directors or Certain - March 26, 2019

Seelos Therapeutics director was just granted 40,000 options - March 21, 2019

Seelos Therapeutics director was just granted 16,000 options - March 21, 2019

Seelos Therapeutics director was just granted 40,000 options - March 21, 2019

Seelos Therapeutics director was just granted 40,000 options - March 21, 2019

Heights Capital Management, Inc. just provided an update on share ownership of Seelos Therapeutics - March 11, 2019

Entry into a Material Definitive - March 8, 2019

Apricus Biosciences just filed a prospectus, suggesting it plans to soon issue some securities - March 8, 2019

Departure of Directors or Certain - March 1, 2019

Securities to be offered to employees in employee benefit plans - Feb. 25, 2019

Apricus: Seelos Therapeutics Completes Acquisition Of Trehalose From Bioblast Pharma - Feb. 19, 2019

Steven Boyd just provided an update on activist position in Apricus Biosciences - Feb. 14, 2019

Statement of acquisition of beneficial ownership by individuals - Feb. 14, 2019

Apricus Biosciences just filed a prospectus, suggesting it plans to soon issue some securities - Feb. 13, 2019

Apricus Biosciences Just Received a Notice of Effectiveness - Feb. 13, 2019

Apricus Biosciences Just Received a Notice of Effectiveness - Feb. 13, 2019

Apricus Biosciences just filed a prospectus, suggesting it plans to soon issue some securities - Feb. 13, 2019

Statement of acquisition of beneficial ownership by individuals - Feb. 8, 2019

Entry into a Material Definitive - Feb. 6, 2019

Registration statement under Securities Act of 1933 - Feb. 1, 2019

Registration statement under Securities Act of 1933 - Feb. 1, 2019

Raj Mehra, Ph.D. just provided an update on activist position in Apricus Biosciences - Jan. 31, 2019

Financial Statements and - Jan. 30, 2019

Apricus Biosciences director just declared ownership of no shares of Apricus Biosciences - Jan. 28, 2019

Major owner of Apricus Biosciences just picked up 3,081,546 shares - Jan. 28, 2019

Apricus Biosciences director just declared ownership of no shares of Apricus Biosciences - Jan. 28, 2019

Apricus Biosciences director just declared ownership of no shares of Apricus Biosciences - Jan. 28, 2019

Apricus Biosciences's See Remarks just declared ownership of no shares of Apricus Biosciences - Jan. 28, 2019

SVP of Apricus Biosciences just disposed of 32,705 shares - Jan. 24, 2019

Current report, item 8.01 - Jan. 24, 2019

Apricus Biosciences's CEO & Secretary just disposed of 44,810 shares - Jan. 24, 2019

Seelos Therapeutics, Inc. Announces Successful Completion Of Its Merger With Apricus Biosciences, Inc. To Advance Late-Stage Pipeline Of Products For Central Nervous System (Cns) Disorders - Jan. 24, 2019

Prospectuses and communications, business combinations - Jan. 16, 2019

Apricus: Unaudited Pro Forma Condensed Combined Financial Information - Jan. 16, 2019

Apricus: Unaudited Pro Forma Condensed Combined Financial Information - Jan. 4, 2019

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. Sarissa Capital Domestic Fund LP 21,203,577 N/A March 3, 2016
2. Uniplan Investment Counsel, Inc. 2,069,121 0.1 March 31, 2020
3. RENAISSANCE TECHNOLOGIES LLC 1,078,379 N/A March 31, 2020
4. SABBY MANAGEMENT, LLC 508,000 0.1 March 31, 2020
5. VANGUARD GROUP INC 239,222 N/A June 30, 2019
6. TOCQUEVILLE ASSET MANAGEMENT L.P. 191,000 N/A March 31, 2020
7. GEODE CAPITAL MANAGEMENT, LLC 154,397 N/A March 31, 2020
8. 1492 Capital Management LLC 150,000 0.1 March 31, 2020
9. BlackRock Inc. 87,977 N/A Dec. 31, 2017
10. BlackRock Inc. 87,036 N/A Dec. 31, 2018
11. BlackRock Inc. 87,036 N/A Sept. 30, 2018
12. ARDSLEY ADVISORY PARTNERS 70,000 N/A March 31, 2020
13. JANE STREET GROUP, LLC 50,100 N/A March 31, 2019
14. Spark Investment Management LLC 35,210 N/A March 31, 2020
15. TWO SIGMA SECURITIES, LLC 28,442 N/A March 31, 2020
16. DAVENPORT & Co LLC 20,000 N/A March 31, 2020
17. Feltz Wealth PLAN Inc. 20,000 N/A March 31, 2020
18. Squarepoint Ops LLC 17,374 N/A March 31, 2020
19. NORTHERN TRUST CORP 15,300 N/A June 30, 2018
20. NORTHERN TRUST CORP 15,300 N/A June 30, 2018
21. NORTHERN TRUST CORP 15,300 N/A June 30, 2018
22. NORTHERN TRUST CORP 15,300 N/A June 30, 2018
23. NORTHERN TRUST CORP 15,300 N/A March 31, 2018
24. BlackRock Advisors LLC 12,376 N/A Sept. 30, 2016
25. BlackRock Fund Advisors 11,422 N/A Sept. 30, 2016
26. BlackRock Inc. 8,641 N/A March 31, 2017
27. BlackRock Inc. 7,190 N/A June 30, 2017
28. VICTORY CAPITAL MANAGEMENT INC 6,738 N/A March 31, 2020
29. BlackRock Institutional Trust Company, N.A. 5,862 N/A Dec. 31, 2016
30. MORGAN STANLEY 4,095 N/A March 31, 2017

Seelos Therapeutics (SEEL)

140
 


Feedback